Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease

  Global program to start in Q4'16 DIVERSITY Phase 3 study in Crohn's disease SELECTION Phase 2b3 study in ulcerative colitis 100 mg and 200 mg once daily doses included